Rennie®-Tal (Tablets) Instructions for Use
Marketing Authorization Holder
Bayer Consumer Care, AG (Switzerland)
Manufactured By
Bayer Bitterfeld, GmbH (Germany)
ATC Code
A02AD04 (Hydrotalcite)
Active Substance
Hydrotalcite (Rec.INN registered by WHO)
Dosage Form
| Rennie®-Tal | Chewable tablets 500 mg: 20 or 50 pcs. |
Dosage Form, Packaging, and Composition
Chewable tablets white in color, round, flat, beveled to the edge, with an imprint in the form of a trademark (the “Bayer” cross) on one side and “TALCID” on the other.
| 1 tab. | |
| Hydrotalcite | 500 mg |
Excipients: mannitol, corn starch, magnesium stearate, sodium saccharin, peppermint flavor, banana flavor.
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (5) – cardboard packs.
Clinical-Pharmacological Group
Antacid drug
Pharmacotherapeutic Group
Antacid agent
Pharmacological Action
An antacid drug. It has a crystalline layered lattice structure with a low content of aluminum and magnesium.
Talcid provides rapid and prolonged neutralization of gastric hydrochloric acid without excessive alkalinization of the gastric contents, maintaining the pH at an optimal therapeutic level between 3 and 5 for 75-90 minutes; it has a gastroprotective effect due to the long-term binding of pepsin, hydrochloric acid, and bile acids; it also activates the stomach’s own protective factors.
Pharmacokinetics
Due to the layered lattice structure of Talcid, the release of aluminum and magnesium ions in the stomach occurs gradually depending on the pH level.
1 g of hydrotalcite has a buffer capacity of 27.8 mEq.
After taking Talcid, the level of aluminum and magnesium in the blood plasma remains within the physiological norm in patients with normal renal function; penetration of aluminum and magnesium ions into the nervous and bone tissues is not observed.
Indications
- Acute and chronic inflammatory diseases of the gastric and duodenal mucosa (including gastritis, duodenitis);
- Gastric and duodenal ulcer;
- Gastrointestinal function disorders associated with improper nutrition or intake of drugs that have an irritating effect on the gastric mucosa;
- Reflux esophagitis;
- Heartburn, belching, feeling of fullness in the stomach.
ICD codes
| ICD-10 code | Indication |
| K21.0 | Gastro-esophageal reflux disease with esophagitis |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| K29 | Gastritis and duodenitis |
| K30 | Functional dyspepsia (digestive disorder) |
| R12 | Heartburn |
| ICD-11 code | Indication |
| DA22.Z | Gastro-esophageal reflux disease, unspecified |
| DA24.Z | Unspecified esophagitis |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA60.Z | Gastric ulcer, unspecified |
| DA63.Z | Duodenal ulcer, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DD90.0 | Globus sensation |
| DD90.1 | Functional dysphagia |
| DD90.3 | Functional dyspepsia |
| DD90.Z | Functional disorders of esophagus or gastroduodenal system, unspecified |
| MD95 | Heartburn |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
For adults, take 1-2 tablets3-4 times per day.
Administer tablets 1-2 hours after meals and before bedtime.
Chew the tablets thoroughly and then swallow with a sufficient amount of water.
For the management of peptic ulcer disease, continue treatment for an average duration of 4 weeks.
For children, a single dose is 1/2 to 1 tablet.
Adjust the frequency of administration for children based on the clinical presentation and severity of symptoms.
Do not exceed the maximum daily dose of 8 tablets.
For symptomatic relief of heartburn, take the tablets as needed, but adhere to the maximum daily dosage.
If symptoms persist beyond 2 weeks of self-medication, consult a physician for further evaluation.
Maintain an interval of 1-2 hours between taking this medication and other drugs to prevent potential interactions.
Adverse Reactions
Possible frequent stools (diarrhea).
When taking Talcid, undesirable side effects are rarely observed and are mainly associated with the long-term use of the drug.
Contraindications
- Individual intolerance.
Use in Pregnancy and Lactation
To date, no cases of undesirable effects have been reported with the use of Talcid during pregnancy and lactation (breastfeeding).
In experimental studies, no teratogenic effect of Talcid was detected.
Use in Renal Impairment
The drug is not recommended for use in patients with impaired renal excretory function.
Pediatric Use
A single dose for children is 1/2-1 tablet.
Special Precautions
1 Talcid tablet contains 0.0086 XE and a negligible amount of sodium saccharin, which allows the drug to be prescribed to patients with diabetes mellitus and arterial hypertension.
The drug is not recommended for use in patients with impaired renal excretory function.
It is not recommended to take Talcid simultaneously with acid-containing beverages (juices, wine).
Talcid should be taken 1-2 hours before or after taking drugs containing iron, derivatives of chenodeoxycholic acid, digoxin, cimetidine, coumarin derivatives.
Overdose
To date, no cases of overdose with Talcid have been reported.
Drug Interactions
With simultaneous use, Talcid reduces the absorption of tetracycline antibiotics, fluoroquinolones (ciprofloxacin, ofloxacin).
Storage Conditions
The drug should be stored in a dry, cool place.
Shelf Life
Shelf life – 5 years.
Pharmacy supply terms
The drug is approved for use as an over-the-counter product.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer